Rescuing Patient Enrollment for a Study of a Rare Mutation

A midsized pharmaceutical company was developing a treatment targeting newly diagnosed acute myeloid leukemia (AML) patients and selected Covance to support their global Phase III trial. Using LabCorp de-identified clinical laboratory data helped the planning teams locate difficult to find patients and increase recruitment.